LYON, France , Aug. 17, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided an update regarding its Ablatherm-HIFU ( High Intensity Focused Ultrasound ) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer.

LYON, France , Aug. 3, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2012 results announcement, which will take place on Thursday, August 30, 2012 , before the opening of the market.

LYON, France , July 25, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today preliminary unaudited top-line financial results for the second quarter ended June 30, 2012. Preliminary total revenue for the second quarter 2012 is expected to

Data Describe HIFU as Therapy for Prostate and Liver Cancer

EDAP Showcases Ablatherm-HIFU Data at International Symposium on Focal Therapy and Imaging

HIFU Therapy Performed by Prestigious St-Augustin Urology Clinic in Bordeaux, France

— CEO Marc Oczachowski Established in U.S. — — CFO Eric Soyer Named General Manager, EDAP TMS France — — CEO EDAP TMS Japan Jean-François Bachelard Named EDAP Asia Operations Supervisor — LYON, France , May 31, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic

Ablatherm-HIFU receives best poster award Unprecedented interest and attendance at EDAP's booth from U.S. urologists LYON, France , May 29, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, showcased its Ablatherm® High Intensity Focused Ultrasound

Additional HIFU Data Presented at Engineering and Urology Society Annual Meeting

EDAP Realigns Strategy to Focus on the U.S.